Spiriva Promotion Should Mention Atrovent HFA Availability, DDMAC Says
This article was originally published in The Pink Sheet Daily
FDA’s ad division calls a Boehringer Ingelheim promotion highlighting the discontinuation of Atrovent MDI misleading.
You may also be interested in...
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.